Low-dose colchicine reduced risk for cardiovascular events in chronic coronary disease

Area of Science:

• Cardiology
• Pharmacology
• Inflammation

Background:

• Chronic coronary disease (CCD) remains a leading cause of mortality worldwide.
• Atherosclerosis, the underlying pathology, involves chronic inflammation.
• Existing treatments primarily focus on risk factor modification and revascularization.

Purpose of the Study:

• To evaluate the efficacy of low-dose colchicine in reducing major adverse cardiovascular events (MACE) in patients with stable chronic coronary disease.
• To assess the anti-inflammatory effects of colchicine in this patient population.

Main Methods:

• A randomized, double-blind, placebo-controlled trial.
• Inclusion of patients with stable coronary artery disease on optimal medical therapy.
• Administration of low-dose colchicine (0.5 mg daily) versus placebo.
• Primary endpoint: composite of cardiovascular death, myocardial infarction, stroke, or coronary revascularization.

Main Results:

• Colchicine significantly reduced the risk of MACE by 23% compared to placebo (hazard ratio, 0.77; 95% CI, 0.61-0.96; P=0.02).
• Reductions were observed in the rates of myocardial infarction and stroke.
• No significant difference in cardiovascular death or coronary revascularization.

Conclusions:

• Low-dose colchicine is effective in reducing cardiovascular events in patients with chronic coronary disease.
• Colchicine represents a novel anti-inflammatory therapeutic strategy for secondary prevention in cardiology.
• Further research is warranted to explore long-term outcomes and optimal dosing.